Identification of Thalidomide-Specific Transcriptomics and Proteomics Signatures during Differentiation of Human Embryonic Stem Cells

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Meganathan, Kesavan ^a   Jagtap, Smita ^a   Wagh, Vilas ^a   Winkler, Johannes ^a   Gaspar, John Antonydas ^a   Hildebrand, Diana ^b   Trusch, Maria ^c   Lehmann, Karola ^d   Hescheler, Jürgen ^a   Schlüter, Hartmut ^b   Sachinidis, Agapios ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

^d PROTEOME FACTORY AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE A2; P21 ACTIVATED KINASE 2; PROTEIN PAFAH1B2; PROTEIN PAFAH1B3; PROTEIN PKM2; PROTEIN RANBP1; PROTEIN RBM14; REGULATOR PROTEIN; THALIDOMIDE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; EMBRYOTOXICITY; GENE EXPRESSION; HEART DEVELOPMENT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIMB DEVELOPMENT; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NERVOUS SYSTEM DEVELOPMENT; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; TERATOGENICITY; TRANSCRIPTOMICS; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

CELL DIFFERENTIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EMBRYONIC DEVELOPMENT; EMBRYONIC STEM CELLS; EXTREMITIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GLUTATHIONE TRANSFERASE; HEART; HUMANS; KINETICS; PROTEIN TRANSPORT; PROTEOMICS; RNA, MESSENGER; THALIDOMIDE; TIME FACTORS; TRANSCRIPTION FACTORS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84865506513     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044228     Document Type: Article

References (54)

1. Kraljevic S, Stambrook PJ, Pavelic K, (2004) Accelerating drug discovery. EMBO Rep 5: 837-842.
2. Seidenberg JM, Anderson DG, Becker RA, (1986) Validation of An Invivo Developmental Toxicity Screen in the Mouse. Teratogenesis Carcinogenesis and Mutagenesis 6: 361-374.
3. Hardin BD, Schuler RL, Burg JR, Booth GM, Hazelden KP, et al. (1987) Evaluation of 60 Chemicals in A Preliminary Developmental Toxicity Test. Teratogenesis Carcinogenesis and Mutagenesis 7: 29-48.
4. Chernoff N, Kavlock RJ, (1982) An in vivo teratology screen utilizing pregnant mice. J Toxicol Environ Health 10: 541-550.
5. Augustine-Rauch K, Zhang CX, Panzica-Kelly JM, (2010) In Vitro Developmental Toxicology Assays: A Review of the State of the Science of Rodent and Zebrafish Whole Embryo Culture and Embryonic Stem Cell Assays. Birth Defects Research Part C-Embryo Today-Reviews 90: 87-98.
6. Scholz G, Genschow E, Pohl I, Bremer S, Paparella M, et al. (1999) Prevalidation of the Embryonic Stem Cell Test (EST)-A New In Vitro Embryotoxicity Test. Toxicol In Vitro 13: 675-681.
7. Seiler AEM, Spielmann H, (2011) The validated embryonic stem cell test to predict embryotoxicity in vitro. Nat Protoc 6: 961-978.
8. Adler S, Pellizzer C, Hareng L, Hartung T, Bremer S, (2008) First steps in establishing a developmental toxicity test method based on human embryonic stem cells. Toxicol In Vitro 22: 200-211.
9. Ito T, Ando H, Handa H, (2011) Teratogenic effects of thalidomide: molecular mechanisms. Cell Mol Life Sci 68: 1569-1579.
10. Miller MT, Stromland K, (1999) Teratogen update: Thalidomide: A review, with a focus on ocular findings and new potential uses. Teratology 60: 306-321.
11. Fratta ID, Sigg EB, Maiorana K, (1965) Teratogenic effects of thalidomide in rabbits, rats, hamsters, and mice. Toxicol Appl Pharmacol 7: 268-286.
12. Teo SK, Evans MG, Brockman MJ, Ehrhart J, Morgan JM, et al. (2001) Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs. Toxicol Sci 59: 160-168.
13. Schumacher H, Blake DA, Gurian JM, Gillette JR, (1968) A comparison of the teratogenic activity of thalidomide in rabbits and rats. J Pharmacol Exp Ther 160: 189-200.
14. Teo SK, Denny KH, Stirling DI, Thomas SD, Morseth S, et al. (2004) Effects of thalidomide on developmental, peri- and postnatal function in female New Zealand white rabbits and offspring. Toxicol Sci 81: 379-389.
15. Ema M, Ise R, Kato H, Oneda S, Hirose A, et al. (2010) Fetal malformations and early embryonic gene expression response in cynomolgus monkeys maternally exposed to thalidomide. Reprod Toxicol 29: 49-56.
16. Hansen JM, Harris C, (2004) A novel hypothesis for thalidomide-induced limb teratogenesis: Redox misregulation of the NF-kappa B pathway. Antioxid Redox Signal 6: 1-14.
17. Knobloch J, Schmitz I, Gotz K, Schulze-Osthoff K, Ruther U, (2008) Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death. Mol Cell Biol 28: 529-538.
18. Knobloch J, Shaughnessy JD Jr, Ruther U, (2007) Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB J 21: 1410-1421.
19. Yabu T, Tomimoto H, Taguchi Y, Yamaoka S, Igarashi Y, et al. (2005) Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 106: 125-134.
20. Parman T, Wiley MJ, Wells PG, (1999) Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nature Medicine 5: 582-585.
21. Hansen JM, Carney EW, Harris C, (1999) Differential alteration by thalidomide of the glutathione content of rat vs. rabbit conceptuses in vitro. Reprod Toxicol 13: 547-554.
22. Hoar RM, (1995) Developmental Toxicity- Extrapolation Across Species. J Am Coll Toxicol 14: 11-20.
23. Winkler J, Sotiriadou I, Chen S, Hescheler J, Sachinidis A, (2009) The potential of embryonic stem cells combined with-omics technologies as model systems for toxicology. Curr Med Chem 16: 4814-4827.
24. Jagtap S, Meganathan K, Gaspar J, Wagh V, Winkler J, et al. (2011) Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol 162: 1743-1756.
25. Wobus AM, Holzhausen H, Jakel P, Schoneich J, (1984) Characterization of a pluripotent stem cell line derived from a mouse embryo. Exp Cell Res 152: 212-219.
26. Dennis G, Sherman B, Hosack D, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: R60.
27. Klose J, Kobalz U, (1995) 2-Dimensional Electrophoresis of Proteins- An Updated Protocol and Implications for A Functional-Analysis of the Genome. Electrophoresis 16: 1034-1059.
28. Zimny-Arndt U, Schmid M, Ackermann R, Jungblut PR, (2009) Classical proteomics: two-dimensional electrophoresis/MALDI mass spectrometry. Methods Mol Biol 492: 65-91.
29. Qu J, Li XF, Novitch BG, Zheng Y, Kohn M, et al. (2003) PAK4 kinase is essential for embryonic viability and for proper neuronal development. J Mol Cell Biol 23: 7122-7133.
30. Yudin D, Fainzilber M, (2009) Ran on tracks - cytoplasmic roles for a nuclear regulator. J Cell Sci 122: 587-593.
31. Knobloch J, Reimann K, Klotz LO, Ruther U, (2008) Thalidomide Resistance Is Based on the Capacity of the Glutathione-Dependent Antioxidant Defense. Molecular Pharmaceutics 5: 1138-1144.
32. Hayes JD, Flanagan JU, Jowsey IR, (2005) Glutathione transferases. Annu Rev Pharmacol Toxicol 45: 51-88.
33. Kodiha M, Stochaj U, (2012) Nuclear transport: a switch for the oxidative stress-signaling circuit? J Signal Transduct 2012: 208650.
34. Assadi AH, Zhang G, McNeil R, Clark GD, D′Arcangelo G, (2008) Pafah1b2 mutations suppress the development of hydrocephalus in compound Pafah1b1; Reln and Pafah1b1; Dab1 mutant mice. Neurosci Lett 439: 100-105.
35. Kodama T, Abe M, Iida S, Ozaki S, Sakai A, et al. (2009) A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma. Clin Lymphoma Myeloma 9: 154-159.
36. Chung F, Lu J, Palmer BD, Kestell P, Browett P, et al. (2004) Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. Clin Cancer Res 10: 5949-5956.
37. Delahunt CS, Lassen LJ, (1964) Thalidomide syndrome in monkeys. Science 146: 1300-1305.
38. Sawin PB, Crary D, Fox RR, Wuest HM, (1965) Thalidomide Malformations and Genetic Background in Rabbit. Experientia 21: 672-677.
39. Stephens TD, (2009) The effect of thalidomide in chicken embryos. Birth Defects Res A Clin Mol Teratol 85: 725-731.
40. Niswander L, (2003) Pattern formation: old models out on a limb. Nat Rev Genet 4: 133-143.
41. Tumpel S, Sanz-Ezquerro JJ, Isaac A, Eblaghie MC, Dobson J, et al. (2002) Regulation of Tbx3 expression by anteroposterior signalling in vertebrate limb development. Dev Biol 250: 251-262.
42. Lu HC, Revelli JP, Goering L, Thaller C, Eichele G, (1997) Retinoid signaling is required for the establishment of a ZPA and for the expression of Hoxb-8, a mediator of ZPA formation. Development 124: 1643-1651.
43. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, et al. (2010) Identification of a primary target of thalidomide teratogenicity. Science 327: 1345-1350.
44. Zakany J, Duboule D, (2007) The role of Hox genes during vertebrate limb development. Curr Opin Genet Dev 17: 359-366.
45. Charite J, de Graaff W, Shen S, Deschamps J, (1994) Ectopic expression of Hoxb-8 causes duplication of the ZPA in the forelimb and homeotic transformation of axial structures. Cell 78: 589-601.
46. Church VL, Francis-West P, (2002) Wnt signalling during limb development. Int J Dev Biol 46: 927-936.
47. Breckenridge RA, Kelly P, Nandi M, Vallance PJ, Mohun TJ, et al. (2010) A role for Dimethylarginine Dimethylaminohydrolase 1 (DDAH1) in mammalian development. Int J Dev Biol 54: 215-220.
48. McFadden DG, Barbosa AC, Richardson JA, Schneider MD, Srivastava D, et al. (2005) The Hand1 and Hand2 transcription factors regulate expansion of the embryonic cardiac ventricles in a gene dosage-dependent manner. Development 132: 189-201.
49. Gove C, Walmsley M, Nijjar S, Bertwistle D, Guille M, et al. (1997) Over-expression of GATA-6 in Xenopus embryos blocks differentiation of heart precursors. EMBO J 16: 1806-1807.
50. Satokata I, Maas R, (1994) Msx1 deficient mice exhibit cleft palate and abnormalities of craniofacial and tooth development. Nat Genet 6: 348-356.
51. Smithells RW, (1973) Defects and disabilities of thalidomide children. Br Med J 1: 269-272.
52. Kajii T, Goto M, (1963) Cleft lip and palate after thalidomide. Lancet 2: 151-152.
53. Poon IKH, Jans DA, (2005) Regulation of nuclear transport: Central role in development and transformation? Traffic 6: 173-186.
54. Mayshar Y, Yanuka O, Benvenisty N, (2011) Teratogen screening using transcriptome profiling of differentiating human embryonic stem cells. J Cell Mol Med 15: 1393-1401.